论文部分内容阅读
目的:观察散结化瘤汤联合米非司酮治疗子宫肌瘤的临床疗效。方法:将80例患者随机分为治疗组和对照组各40例,对照组予米非司酮治疗;治疗组在对照组治疗的基础上加服散结化瘤汤,2组疗程均为3月;采用B超检测治疗前后肌瘤体积,检测治疗前后血清卵泡刺激素(FSH)、黄体生成素(LH)、雌二醇(E2)、孕激素(P)水平,进行治疗前后主要症状、体征评分。结果:临床总有效率治疗组为92.5%,对照组为75.0%,2组比较,差异有显著性意义(P<0.05)。治疗后治疗组子宫肌瘤平均体积小于对照组(P<0.01)。治疗后治疗组主要症状、体征评分均低于对照组(P<0.01)。治疗后2组血清FSH、LH、E2及P水平均较治疗前下降(P<0.01);治疗组E2水平下降低于对照组(P<0.05)。结论:散结化瘤汤联合米非司酮能缩小肌瘤体积,调节激素水平,改善患者症状,提高临床疗效,值得临床推广使用。
Objective: To observe the clinical efficacy of Sanjie Huitang combined with mifepristone in the treatment of uterine fibroids. Methods: Eighty patients were randomly divided into treatment group and control group, with 40 cases in each group. The control group was treated with mifepristone. The treatment group was given Sanjiehua Decoction on the basis of the control group. The treatment groups were 3 Month before treatment; the volume of fibroids before and after treatment was detected by B-mode ultrasound; the levels of serum FSH, LH, E2 and progesterone before and after treatment were measured before and after treatment. The main symptoms, Signs score. Results: The total clinical effective rate was 92.5% in the treatment group and 75.0% in the control group. There was significant difference between the two groups (P <0.05). After treatment, the average volume of uterine fibroids in the treatment group was smaller than that in the control group (P <0.01). After treatment, the main symptoms and signs of the treatment group were lower than those of the control group (P <0.01). Serum levels of FSH, LH, E2 and P in the two groups after treatment were lower than those before treatment (P <0.01). The E2 level in the treatment group was lower than that in the control group (P <0.05). Conclusion: Sanjiezhitang combined with mifepristone can reduce the volume of fibroids, regulate hormone levels, improve the symptoms of patients and improve the clinical curative effect, which is worthy of clinical promotion and use.